deltatrials
Completed PHASE1/PHASE2 INTERVENTIONAL 3-arm NCT05715346

LEV102 Topical Gel in Acquired Blepharoptosis

A Phase 1/2a Study of LEV102 Topical Gel in Subjects With Acquired Blepharoptosis

Sponsor: Levation Pharma, Ltd.

Conditions Acquired Blepharoptosis
Interventions LEV102 1.0% LEV102 2.0% Vehicle
Updated 6 times since 2023 Last updated: Oct 22, 2024 Started: Feb 23, 2023 Primary completion: Jun 24, 2023 Completion: Jun 24, 2023
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1/PHASE2 clinical study on Acquired Blepharoptosis, this trial is completed. The trial is conducted by Levation Pharma, Ltd. and has accumulated 6 data snapshots since 2023. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

~Mar 2023 – ~Apr 2023 · 31 days · monthly snapshot~Apr 2023 – ~Apr 2024 · 12 months · monthly snapshotRecruiting~Apr 2024 – ~Jul 2024 · 3 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Dec 2024 · 3 months · monthly snapshot~Dec 2024 – present · 19 months · monthly snapshotCompleted

Change History

6 versions recorded

  1. Dec 2024 — Present [monthly]

    Completed PHASE1/PHASE2

  2. Sep 2024 — Dec 2024 [monthly]

    Completed PHASE1/PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1/PHASE2

    Phase: PHASE1_PHASE2 → PHASE1/PHASE2

  4. Apr 2024 — Jul 2024 [monthly]

    Completed PHASE1_PHASE2

    Status: Recruiting → Completed

  5. Apr 2023 — Apr 2024 [monthly]

    Recruiting PHASE1_PHASE2

    Status: Not Yet Recruiting → Recruiting

▶ Show 1 earlier version

  1. Mar 2023 — Apr 2023 [monthly]

    Not Yet Recruiting PHASE1_PHASE2

    First recorded

Feb 2023

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Levation Pharma, Ltd.
Data source: Levation Pharma, Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations